🚀 VC round data is live in beta, check it out!
Guangzhou Wondfo Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Guangzhou Wondfo Biotech and similar public comparables like Daan Gene, Azenta, Ramsay Santé, Sinocare and more.
Guangzhou Wondfo Biotech Overview
About Guangzhou Wondfo Biotech
Guangzhou Wondfo Biotech Co Ltd manufactures medical diagnostic tests. Its products include immunodiagnostic rapid test kits, including fertility, which include pregnancy HCG, ovulation LH, and others. The company's products are used in a clinical test, field test, and personal health management, among others.
Founded
1992
HQ
Employees
N/A
Website
Financials (FY)
EV
$1B
Guangzhou Wondfo Biotech Financials
Guangzhou Wondfo Biotech reported last fiscal year revenue of $449M and EBITDA of $155M.
In the same fiscal year, Guangzhou Wondfo Biotech generated $288M in gross profit, $155M in EBITDA, and $82M in net income.
Revenue (LTM)
Guangzhou Wondfo Biotech P&L
In the most recent fiscal year, Guangzhou Wondfo Biotech reported revenue of $449M and EBITDA of $155M.
Guangzhou Wondfo Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $449M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $288M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 64% | XXX | XXX | XXX |
| EBITDA | — | XXX | $155M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 21% | XXX | XXX | XXX |
| Net Profit | — | XXX | $82M | XXX | XXX | XXX |
| Net Margin | — | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Guangzhou Wondfo Biotech Stock Performance
Guangzhou Wondfo Biotech has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Guangzhou Wondfo Biotech's stock price is $2.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGuangzhou Wondfo Biotech Valuation Multiples
Guangzhou Wondfo Biotech trades at 2.4x EV/Revenue multiple, and 6.9x EV/EBITDA.
EV / Revenue (LTM)
Guangzhou Wondfo Biotech Financial Valuation Multiples
As of April 20, 2026, Guangzhou Wondfo Biotech has market cap of $1B and EV of $1B.
Equity research analysts estimate Guangzhou Wondfo Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guangzhou Wondfo Biotech has a P/E ratio of 14.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 11.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.7x | XXX | XXX | XXX |
| P/E | — | XXX | 14.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 168.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Guangzhou Wondfo Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Guangzhou Wondfo Biotech Margins & Growth Rates
Guangzhou Wondfo Biotech's revenue in the last fiscal year grew by 11%.
Guangzhou Wondfo Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 10% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Guangzhou Wondfo Biotech Public Comps
See public comps and valuation multiples for other Laboratory Services and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Guangzhou Wondfo Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Daan Gene | XXX | XXX | XXX | XXX | XXX | XXX |
| Azenta | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Santé | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocare | XXX | XXX | XXX | XXX | XXX | XXX |
| NeoGenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guangzhou Wondfo Biotech M&A Activity
Guangzhou Wondfo Biotech acquired XXX companies to date.
Last acquisition by Guangzhou Wondfo Biotech was on XXXXXXXX, XXXXX. Guangzhou Wondfo Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Guangzhou Wondfo Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGuangzhou Wondfo Biotech Investment Activity
Guangzhou Wondfo Biotech invested in XXX companies to date.
Guangzhou Wondfo Biotech made its latest investment on XXXXXXXX, XXXXX. Guangzhou Wondfo Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Guangzhou Wondfo Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Guangzhou Wondfo Biotech
| When was Guangzhou Wondfo Biotech founded? | Guangzhou Wondfo Biotech was founded in 1992. |
| Where is Guangzhou Wondfo Biotech headquartered? | Guangzhou Wondfo Biotech is headquartered in China. |
| Is Guangzhou Wondfo Biotech publicly listed? | Yes, Guangzhou Wondfo Biotech is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech trades under 300482 ticker. |
| When did Guangzhou Wondfo Biotech go public? | Guangzhou Wondfo Biotech went public in 2015. |
| Who are competitors of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech main competitors are Daan Gene, Azenta, Ramsay Santé, Sinocare. |
| What is the current market cap of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech's current market cap is $1B. |
| What is the current revenue of Guangzhou Wondfo Biotech? | Guangzhou Wondfo Biotech's last fiscal year revenue is $449M. |
| What is the current EV/Revenue multiple of Guangzhou Wondfo Biotech? | Current revenue multiple of Guangzhou Wondfo Biotech is 2.4x. |
| Is Guangzhou Wondfo Biotech profitable? | No, Guangzhou Wondfo Biotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.